An observational study in Colon Cancer and Endometrial Cancer, sponsored by Data Collection Analysis Business Management. Status unknown at 1 site in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-23.
Sponsored by Data Collection Analysis Business Management · Observational
Among 1,122 studies in Colonic Neoplasms with a site in United States — 116 open to participants now, 190 under way, 14 of them phase 3. Colonic Neoplasms · United States.
Among the 1,122 studies in Colonic Neoplasms with a site in United States, this one is the 95th largest by planned enrollment of the 181 observational ones that give a count, is one of 43 that started in 2017, is one of 181 observational ones, and was the 778th registered.
2,457 studies on the registry are indexed under Colonic Neoplasms; 458 are open to participants now.
Browse Colonic Neoplasms studies →116 of the 1,122 studies in Colonic Neoplasms with a site in United States are open now. Recruiting first, the newest first:
Solstice Oncology, Inc. · Sites in United States, Belgium, Italy and 3 more countries
Ages 18+
LTZ Therapeutics, Inc. · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Ages 18+
BigHat Biosciences, Inc. · Sites in United States
Ages 18+
Fox Chase Cancer Center · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 326 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 71 (22%) stop at 75 or younger; 19 take children under 18; 34 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 353 · Phase 2 341 · Phase 3 87 · Phase 4 10
First in 1981; this study’s year is marked. 43 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is below the median of 227 across 555 observational studies indexed under Colonic Neoplasms.
Median enrollment 50 across the 864 interventional studies, 220 across the 181 observational. Of the 839 that completed or were terminated, 241 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
228 of 1,122 have an industry lead sponsor. The 10 most frequent:
Data Collection Analysis Business Management is the lead sponsor of 9 studies on the registry; none are open to participants now.
Data Collection Analysis Business Management has 1 study filed under Colonic Neoplasms — fewer than ten, so there is no comparison to draw.
61 of the studies in Colonic Neoplasms with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03803553Phase 3Massachusetts General HospitalIdentification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer | 2026-12 |
| NCT06191185University of California, San FranciscoIMProving Adherence to Colonoscopy Through Teams and Technology | 2026-11-27 |
| NCT07023731Arvinas Inc.A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | 2026-11-30 |
| NCT00579163Memorial Sloan Kettering Cancer CenterAscertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers | 2026-12 |
| NCT07224464New Phase Ltd.The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. | 2026-12 |
Add all 61 to your calendar (.ics) → With an account.
Among the 1,122 studies in Colonic Neoplasms with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Increase surveillance for LYNCH Syndrome
The purpose of this minimal risk, observational survey is to increase surveillance for Lynch Syndrome (hereditary non-polyposis colon cancer), Colorectal, and Endometrial cancer, also to determine targeted risk-reducing and preventative strategies.
collecting data and reviewing the Principal Investigators' (P.I.) Standard Operating Procedures (SOP) on Lynch genetic testing and changes made to their specific SOP.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Must be a Medical Practitioner
Exclusion Criteria:
LYNCH genetic testing
Provider Structures and Processes
Plan of Care Changes due to LYNCH genetic testing. Provider based observational survey system on the health and well-being of patients and populations
Time frame: 36 months
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2017 (actual). Primary completion is estimated for Oct 2020, 36 months after the start.
Of 186 non-industry observational studies under Colonic Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 116. This study's planned 36 months is below that.
Counting every sponsor, half of 224 studies reached it within 50 months; a quarter within 27 and three quarters within 116.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Data Collection Analysis Business Management